Analysts have been eager to weigh in on the Healthcare sector with new ratings on Regeneron (NASDAQ:REGN) and Zealand Pharma A/S (NASDAQ:ZEAL).
Regeneron (REGN)
Canaccord Genuity analyst John Newman maintained a Hold rating on Regeneron today and set a price target of $390. The company’s shares opened today at $373.
Newman commented:
“We remind investors that the PDS system is still at an early stage of development and safety data has yet to be released to determine its clinical applicability. Furthermore, we believe NVS is trying to “fit” brolucizumab to a 12-week dosing schedule rather than maximize efficacy for wet AMD, which may not be a good approach since only 57% of the HAWK study and 52% of the HARRIER study were subjected to Q12W dosing, indicating that a significant number of patients still require more frequent dosing. We maintain the view that REGN will still face meaningful headwinds in growth, given the increase in EYLEA discounting and that US EYLEA sales will make up the majority of the revenues for some time to come.”
According to TipRanks.com, Newman is a 5-star analyst with an average return of 16.3% and a 44.1% success rate. Newman covers the Healthcare sector, focusing on stocks such as Hutchison China MediTech Ltd, Synergy Pharmaceuticals Inc, and Atara Biotherapeutics.
The word on The Street in general, suggests a Hold analyst consensus rating for Regeneron with a $387.50 average price target, implying a 3.9% upside from current levels. In a report issued on August 3, Robert W. Baird also downgraded the stock to Hold with a $405 price target.
.
See today’s analyst top recommended stocks >>
Zealand Pharma A/S (ZEAL)
In a report released today, Alan Carr from Needham maintained a Buy rating on Zealand Pharma A/S, with a price target of $26. The company’s shares opened today at $14.11.
Carr observed:
“Zealand provided a 2Q18 corporate update in a conference call yesterday. Several milestones are expected next month, including results from dasiglucagon rescue pen Phase 3 trial in Acute Severe Hypoglycemia, initiation of glepaglutide Phase 3 trial in Short Bowel Syndrome (SBS), initiation of dasiglucagon Phase 3 program in Congenital Hyperinsulinism (CHI) and initiation of dasiglucagon Phase 2b dual-pump Diabetes trial. Both lead assets are undervalued, in our view, and we believe upcoming events in 2H18 may serve as catalysts for the stock. BUY.”
According to TipRanks.com, Carr is a 3-star analyst with an average return of 3.1% and a 41.3% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Rhythm Pharmaceuticals Inc, and Lexicon Pharmaceuticals.
Currently, the analyst consensus on Zealand Pharma A/S is a Moderate Buy with an average price target of $26.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
